Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDH2 | P40926 | 6/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.53 |
| ▸ | CDK1 | P06493 | 5/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.53 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25556206 | 0.85 | CDK1 (0.51) | MDH2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL29783245 | 0.85 | CDK1 (0.51) | MDH2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL6872991 | 0.85 | CCNB2 (0.43) | MDH2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5683914 | 0.84 | CYP3A4 (0.44) | MDH2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL6871281 | 0.83 | MEN1 (0.42) | MDH2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL771568 | 0.83 | KDM4E (0.43) | MDH2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5025689 | 0.83 | MAPK1 (0.43) | MDH2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL6871811 | 0.83 | CCNB2 (0.42) | MDH2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL17183162 | 0.79 | CES1 (0.46) | MDH2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2616936 | 0.79 | GSK3B (0.51) | CCNB2CDK1CCNB1CCNB3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748691-B1 | PLANT GROWTH REGULATION | BAYER CROPSCIENCE AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| EP-1748691-A1 | PLANT GROWTH REGULATION | Bayer CropScience GmbH (DE) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005107471-A1 | PLANT GROWTH REGULATION | BAYER CROPSCIENCE GMBH (DE) | 2005-11-17 | — | — | WO | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1399448-B1 | IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2004-12-01 | — | — | EP | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-1399448-A1 | IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| US-6686352-B2 | USEFUL AS COGNITIVE ENHANCER OR FOR THERAPY OF COGNITIVE DISORDERS LIKE ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030055042-A1 | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives | F. HOFFMANN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-03-20 | — | — | US | disclosed |
| WO-2002094834-A1 | IMIDAZO [1,5-A] PYRIMIDO [5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055042-A1 | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives | GALR1, GALR2, ADRA1A | MDH2 2825/4885CCNB2 3544/4885CDK1 3196/4885 |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | MDH2 115/4885CCNB2 1062/4885CDK1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.